Loading…
SDGR
Schrodinger, Inc.
NASDAQ· Healthcare· Health Information Services
$19.70-3.48%
Key metrics
- Market cap
- $1.47B
- P/E
- —
- Forward P/E
- —
- P/B
- 4.4x
- Dividend yield
- —
- EPS
- -$0.73
- ROE
- -16.18%
- Profit margin
- -20.98%
- Revenue growth
- +7.50%
- Beta
- 1.66
- 52-week high
- $23.02
- 52-week low
- $10.95
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
- 850
- New York, United States
Company description provided by Yahoo Finance.